Shares of Amgen (AMGN) are jumping Friday morning after the company showed confidence in early results from a GLP-1 weight-loss drug that is in development...
) are jumping Friday morning after the company showed confidence in early results from a GLP-1 weight-loss drug that is in development to treat obesity. The pharmaceutical giant joins The Morning Brief to break down the latest developments from Amgen and its outlook on use cases for the drug in question, MariTide.
Toronto influencer Susete Isabel says she initially ignored her stage 4 cancer symptoms: 'It's a bad sign'An insurance company has denied newborn twins a one-time genetic treatment that could cure their spinal muscular atrophy — otherwise they are likely to die before their second birthdayCanadian dollar rebounds as Fed keeps rate cuts on the table
WASHINGTON — The Federal Reserve on Wednesday emphasized that inflation has remained stubbornly high in recent months and said it doesn’t plan to cut interest rates until it has “greater confidence” that price increases are slowing sustainably to its 2% target. The Fed issued its decision in a statement after its latest meeting, at which it kept its key rate at a two-decade high of roughly 5.3%.
Revenue Estimates Anjalee Khemlani Pharmaceutical Giant Obesity
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Amgen shares jump after teasing 'encouraging' weight loss dataExplore stories from Atlantic Canada.
Read more »
Amgen, DraftKings, Live Nation: Trending tickersShares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology...
Read more »
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug dataExplore stories from Atlantic Canada.
Read more »
Futures rise on Apple, Amgen boost; jobs data on tapExplore stories from Atlantic Canada.
Read more »
Futures rise on Apple, Amgen boost; jobs data on tapApple jumped 5.8%, outpacing other megacap stocks in premarket trading after the iPhone maker unveiled a record $110 billion share buyback program and beat...
Read more »
Novo Slides as Amgen Update Fuels Obesity Drug Competition Fears(Bloomberg) -- Novo Nordisk A/S shares slid on Friday as a US rival’s comments on an experimental obesity drug gave rise to concerns about potential new...
Read more »